Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823168 | 1.00 | HTR6 (0.39) | HTR6 | |
| SCHEMBL139587 | 0.98 | HTR6 (0.41) | HTR6 | |
| SCHEMBL1427870 | 0.94 | HTR6 (0.36) | HTR6 | |
| SCHEMBL3011186 | 0.90 | HTR6 (0.38) | HTR6 | |
| SCHEMBL3959219 | 0.90 | HTR6 (0.38) | HTR6 | |
| SCHEMBL236429 | 0.85 | HTR6 (0.36) | HTR6 | |
| SCHEMBL1829431 | 0.83 | HTR6 (0.44) | HTR6 | |
| SCHEMBL7050656 | 0.80 | — | — | |
| SCHEMBL946157 | 0.80 | CYP2A13 (0.31) | — | |
| SCHEMBL5050538 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | claimed |
| EP-4288104-A1 | LIPIDS SUITABLE FOR NUCLEIC ACID DELIVERY | Ramot at Tel-Aviv University Ltd. (IL) | 2023-12-13 | — | — | EP | claimed |
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | claimed |
| CN-116323589-A | Pyridone compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2023-06-23 | — | — | CN | claimed |
| EP-4192822-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | claimed |
| WO-2022168085-A1 | LIPIDS SUITABLE FOR NUCLEIC ACID DELIVERY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-08-11 | — | — | WO | claimed |
| CN-114075221-A | Substituted heteroaryl compounds, compositions and uses thereof | 广东东阳光药业有限公司 | 2022-02-22 | — | — | CN | claimed |
| EP-3890716-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | claimed |
| CN-113164418-A | Combination therapy | 米拉蒂治疗股份有限公司 | 2021-07-23 | — | — | CN | claimed |
| EP-3849534-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| EP-1545532-A2 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-29 | — | — | EP | claimed |
| US-20040058934-A1 | Heterocyclic compounds | JANSSEN PHARMACEUTIC, N.V. (BE) | 2004-03-25 | — | — | US | claimed |
| WO-2004022060-A2 | (1H-BENZOIMIDAZOL-2-YL)-(PIPERAZINYL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | claimed |
| EP-1216247-A1 | IMIDAZOIMIDAZOLES AND TRIAZOLES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-06-26 | — | — | EP | claimed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | claimed |
| EP-0783505-B1 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE | NOVARTIS AG (CH) | 2001-03-07 | — | — | EP | claimed |
| WO-2001007440-A1 | IMIDAZOIMIDAZOLES AND TRIAZOLES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-01 | — | — | WO | claimed |
| US-5583135-A | TREATING SYSTEMIC LUPUS ERYTHEMATOSIS OR MELANOMA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-10 | — | — | US | claimed |
| US-5561225-A | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages | SOUTHERN RESEARCH INSTITUTE (US) | 1996-10-01 | — | — | US | claimed |
| US-5374416-A | Nitrogenous macrocyclic ligands, polymetallic complexes and diagnostic and therapeutic composition | GUERBET S.A. (FR) | 1994-12-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | PNPO, PDXK, C5 | HTR6 1900/4885 |
| US-20040058934-A1 | Heterocyclic compounds | HRH4, HRH2, HRH1 | HTR6 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.